Piribo: Financial Markets Research: ASCO Review Part II, new publication announcement

Piribo, the online destination for business intelligence for the biotech and pharmaceutical industry, has now added a new report called “Financial Markets Research: ASCO Review Part II - A summary of highlights presented at the ASCO 2006 Annual Meeting”. http://www.piribo.com/publications/finance_investment/financial_markets_research_asco_review_part_ii.html

ASCO features key presentations in the oncology area, and is generally the most important week of the year for oncology. Presents Datamonitor's comments on the most important events at the 2006 conference.

Highlights
Continuing a disappointing weekend, Nexavar was unable to show a statistically significant survival benefit in second-line metastatic renal cell carcinoma (RCC) in an update from the trial that led to its FDA approval. But, we believe that reports that Nexavar has 'failed' to show a survival benefit appear to be misleading.We note that while data presented at ASCO has given Sutent frontrunner status in first-line therapy in RCC, results from trials examining various targeted agents have suggested that these therapies may be used sequentially in metastatic disease.Results of numerous trials in multiple myeloma (MM) with Thalomid, Revlimid, and Velcade proved overwhelmingly positive, with high efficacy and superiority over standard regimens in both front-line and later-line settings. The optimal regimen is being evaluated in ongoing clinical trials, from which we expect data to emerge over the next two years.

Scope
- A summary of highlights presented at ASCO 2006 on Monday June 4, 2006, as well as information on related presentations from earlier in the conference
- Drugs covered include Celgene's Thalomid (thalidomide) & Revlimid (lenalidomide), Genentech's Avastin (bevacizumab), Millennium's Velcade (bortezomib)
Reasons to Purchase
- Identify the most important events that occurred at ASCO 2006
- Understand the impact of key data presentations on the potential future dynamics of the oncology market

Contents
Summary
Asco Coverage
Tykerb (Lapatinib) Highlights
Highlights In Chronic Myeloid Leukemia
Highlights In Renal Cell Carcinoma
Erbitux (Cetuximab) Highlights
Highlights In Non-Small Cell Lung Cancer
Denosumab Highlights
Appendix

“Financial Markets Research: ASCO Review Part II - A summary of highlights presented at the ASCO 2006 Annual Meeting” is available from Piribo. For more information go to: http://www.piribo.com/publications/finance_investment/financial_markets_research_asco_review_part_ii.html

Piribo Product ID: DAT542

About Piribo.
Piribo (http://www.piribo.com) is a UK-based independent online store supplying business information on the pharmaceutical and biotechnology industries. The website now carries over 3,800 English language titles including, market reports, studies and books and is the UK’s largest online biopharma information store. Subscribers receive a free monthly newsletter and email alerts on new titles in their areas of interest. The company was established in 2004.